Press Releases Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
11.9 ^USD	0.00%		-0.63%	+5.97%

08/05	Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oculis Holding - Increase in share capital	21/05	AQ
Oculis updates share capital for its existing at-the-market offering program	18/05	GL
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K	09/05	PU
Oculis : Form 6-K	09/05	PU
Oculis Reports Q1 2024 Financial Results and Provides Company Updates	09/05	GL
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis	09/05	AQ
Oculis Publishes Invitation to the Annual General Meeting	08/05	GL
Oculis to Present at Bank of America Global Healthcare Conference	06/05	AQ
Oculis Publishes Invitation to the Annual General Meeting	30/04	AQ
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market	22/04	GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market	11/04	AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development	10/04	AQ
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	08/04	AQ
Oculis to Participate at Upcoming April Investor Conferences	04/04	AQ
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress	18/03	AQ
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments	28/02	AQ
Oculis to Present at Upcoming February Investor Conferences	29/01	AQ
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024	22/01	AQ
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	20/12	AQ
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema	18/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oculis Holding AG

Equities

OCS

CH1242303498

Press Releases

Filters